Sab BiotherapeuticsSABS
13F holders, Q4 2024 (December 31)25holders
4new positions
5sold out
1famous investor
$3.84avg. 13F price*
At the end of Q4 2024, 25 institutions reported holding Sab Biotherapeutics Inc. (SABS) in their 13F filings, unchanged from Q3 2024. 4 opened new positions and 5 sold out. The largest holders were BVF Inc. ($3.5M), Marshall Wace, LLP ($1.8M) and Sessa Capital IM, L.P. ($1.7M). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Sab Biotherapeutics Inc.
- CUSIP
- 78397T202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $49K |
| Exits | 5 | $1.8M |
All 13F filers, Q3 2024 → Q4 2024: 156,333 shares bought and 694,980 shares sold, net −538,647 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 25 holders
| BVF Inc. | 0.12% | No change | 917,826 | $3.5M |
| Marshall Wace, LLP | 0.00% | No change | 459,168 | $1.8M |
| Sessa Capital IM, L.P. | 0.07% | No change | 458,457 | $1.7M |
| Vanguard Group Inc. | 0.00% | Add +0.4% | 277,375 | $1.1M |
| HB Wealth Management, LLC | 0.01% | Add +118.6% | 237,400 | $982K |
| Geode Capital Management, LLC | 0.00% | Add +18.8% | 80,234 | $307K |
| Pathstone Holdings, LLC | 0.00% | No change | 50,650 | $192K |
| Diadema Partners LP | 0.13% | — | 30,000 | $114K |
| Millennium Management | 0.00% | Reduce -43.4% | 29,411 | $112K |
| BlackRock, Inc. | 0.00% | Add +2.0% | 22,604 | $86K |
| NorthCoast Asset Management LLC | 0.00% | No change | 19,201 | $73K |
| First PREMIER Bank | 0.02% | Reduce -2.1% | 18,986 | $72K |
| Kestra Advisory Services, LLC | 0.00% | No change | 11,930 | $45K |
| Northern Trust Corp. | 0.00% | New | 11,387 | $43K |
| Osaic Holdings, Inc. | 0.00% | Add +11.3% | 5,047 | $19K |
| UBS Group AG | 0.00% | New | 1,083 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -59.6% | 842 | $3K |
| Morgan Stanley | 0.00% | Reduce -14.3% | 599 | $2K |
| Federation des caisses Desjardins du Quebec | 0.00% | New | 250 | $949 |
| GS Investments, Inc. | 0.00% | No change | 200 | $759 |
| MAI Capital Management | 0.00% | New | 130 | $494 |
| JPMorgan Chase & Co. | 0.00% | Reduce -0.9% | 105 | $401 |
| Sachetta, LLC | 0.00% | No change | 100 | $380 |
| Bank of America Corp. | 0.00% | Reduce -34.0% | 64 | $243 |
| Harbour Investments, Inc. | 0.00% | No change | 50 | $190 |
"% of holder's portfolio" is SABS's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. the manager owns.